EUVIMEDEUVIMED entdecken
Crossref

Characterization of the Epileptogenic Phenotype and Response to Antiseizure Medications in Lissencephaly Patients

Christiane R Proepper, Sofia M Schuetz, Lisa-Maria Schwarz, Katja von Au, Thomas Bast, Nathalie Beaud, Ingo Borggraefe, Friedrich Bosch, Joerg Budde, Melanie Busse, Jena Chung, Otfried Debus und 23 weitere

Neuropediatrics · 01.12.2024 · 55 (06) · 410-419

DOI: 10.1055/s-0044-1789014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropediatrics, erschienen am 01.12.2024. Verfasst von Christiane R Proepper und 34 weiteren Autor:innen. Beteiligte Einrichtung: University Children's Hospital Regensburg (KUNO), University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Anticonvulsants, Phenotype, Lissencephaly. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with lissencephaly typically present with severe psychomotor retardation and drug-resistant seizures. The aim of this study was to characterize the epileptic phenotype in a genotypically and radiologically well-defined patient cohort and to evaluate the response to antiseizure medication (ASM). Therefore, we retrospectively evaluated 47 patients of five genetic forms (LIS1/PAFAH1B1, DCX, DYNC1H1, TUBA1A, TUBG1) using family questionnaires, standardized neuropediatric assessments, and patients' medical reports.

Results

All but two patients were diagnosed with epilepsy. Median age at seizure onset was 6 months (range: 2.1–42.0), starting with epileptic spasms in 70%. Standard treatment protocols with hormonal therapy (ACTH or corticosteroids) and/or vigabatrin were the most effective approach for epileptic spasms, leading to seizure control in 47%. Seizures later in the disease course were most effectively treated with valproic acid and lamotrigine, followed by vigabatrin and phenobarbital, resulting in seizure freedom in 20%. Regarding psychomotor development, lissencephaly patients presenting without epileptic spasms were significantly more likely to reach various developmental milestones compared to patients with spasms.

Conclusion

Classic lissencephaly is highly associated with drug-resistant epilepsy starting with epileptic spasms in most patients. The standard treatment protocols for infantile epileptic spasms syndrome lead to freedom from seizures in around half of the patients. Due to the association of epileptic spasms with an unfavorable course of psychomotor development, early and reliable diagnosis and treatment of spasms should be pursued. For epilepsies occurring later in childhood, ASM with valproic acid and lamotrigine, followed by vigabatrin and phenobarbital, appears to be most effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsPhenotypeLissencephalyHumansFemaleMaleInfantChild, PreschoolRetrospective StudiesChildDoublecortin ProteinEpilepsy1-Alkyl-2-acetylglycerophosphocholine EsteraseAdolescentAdultVigabatrinMicrotubule-Associated ProteinsYoung Adult

Substanzen

AnticonvulsantsDoublecortin ProteinDCX protein, humanPAFAH1B1 protein, human1-Alkyl-2-acetylglycerophosphocholine EsteraseVigabatrinMicrotubule-Associated Proteins

Autor:innen und Institutionen

  • University Children's Hospital Regensburg (KUNO), University Hospital Regensburg, Regensburg, Germany.
  • Department of Ophthalmology, University Hospital Regensburg, Regensburg, Germany.
  • Department of Neurology, Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany.
  • Department of Pediatrics, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
  • Epilepsy Center Kork, Kehl, Germany.
  • Pediatric Practice, Garding, Germany.

Zitieren

APA

Proepper, C. R., Schuetz, S. M., Schwarz, L. M., Au, K. V., Bast, T., Beaud, N., Borggraefe, I., Bosch, F., Budde, J., Busse, M., Chung, J., Debus, O., Diepold, K., Fries, T., Gersdorff, G. V., Haeussler, M., Hahn, A., Hartlieb, T., Heiming, R., …, & Geis, T. (2024). Characterization of the Epileptogenic Phenotype and Response to Antiseizure Medications in Lissencephaly Patients. Neuropediatrics, 55(06), 410-419. https://doi.org/10.1055/s-0044-1789014

Vancouver

Proepper CR, Schuetz SM, Schwarz LM, Au KV, Bast T, Beaud N, et al. Characterization of the Epileptogenic Phenotype and Response to Antiseizure Medications in Lissencephaly Patients. Neuropediatrics. 2024;55(06):410-419. doi:10.1055/s-0044-1789014

BibTeX
@article{Proepper2024,
  author = {Proepper, Christiane R and Schuetz, Sofia M and Schwarz, Lisa-Maria and Au, Katja von and Bast, Thomas and Beaud, Nathalie and Borggraefe, Ingo and Bosch, Friedrich and Budde, Joerg and Busse, Melanie and Chung, Jena and Debus, Otfried and Diepold, Katharina and Fries, Thomas and Gersdorff, Gero von and Haeussler, Martin and Hahn, Andreas and Hartlieb, Till and Heiming, Ralf and Herkenrath, Peter and Kluger, Gerhard and Kreth, Jonas H and Kurlemann, Gerhard and Moeller, Peter and Morris-Rosendahl, Deborah J and Panzer, Axel and Philippi, Heike and Ruegner, Sophia and Toepfer, Carolina and Vieker, Silvia and Wiemer-Kruel, Adelheid and Winter, Anika and Schuierer, Gerhard and Hehr, Ute and Geis, Tobias},
  title = {Characterization of the Epileptogenic Phenotype and Response to Antiseizure Medications in Lissencephaly Patients},
  journal = {Neuropediatrics},
  year = {2024},
  volume = {55},
  number = {06},
  pages = {410--419},
  doi = {10.1055/s-0044-1789014}
}
Kostenlos starten →